- Home
- CRSP
as 11-15-2024 4:00pm EST
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 4.0B | IPO Year: | 2016 |
| Target Price: | $73.69 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $43.42 - $91.10 | Next Earning Date: | 11-05-2024 |
| Revenue: | $202,829,000 | Revenue Growth: | 19.31% |
| Revenue Growth (this year): | -93.22% | Revenue Growth (next year): | 526.27% |
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | CRSP | Chief Executive Officer | Nov 11 '24 | Sell | $55.85 | 30,000 | $1,668,678.36 | 203,419 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Oct 13 '24 | Sell | $46.28 | 1,089 | $50,398.92 | 62,597 |
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Motley Fool
2 days ago
Where Will CRISPR Therapeutics Be in 3 Years?
GlobeNewswire
3 days ago
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
Motley Fool
4 days ago
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
Yahoo Finance Video
9 days ago
Elon Musk will be 'vitally important' in Trump admin: Cathie Wood
Motley Fool
9 days ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
GlobeNewswire
10 days ago
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Simply Wall St.
10 days ago
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Compare CRSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.